



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Anti-Norovirus GII.4 P domain [A1431] Bulk Size Ab02974-16.0-BT

This antibody does not have a J-chain.

This reformatted human antibody was made using the variable domain sequences of the original Human IgG1 format for improved compatibility with existing reagents assays and techniques.

Isotype and Format: Human IgA1, Kappa

Clone Number: A1431

Alternative Name(s) of Target: VP1; NoV; HuNoV; NoV VP1; capsid protein VP1; major capsid protein; Norovirus GII.4; Norwalk virus

UniProt Accession Number of Target Protein: S5YAA0

Published Application(s): neutralize, Block, ELISA

Published Species Reactivity: Norovirus

Immunogen: The original antibody was isolated from an anti-NoV GII.4c IgG serum antibody repertoire generated from three donors that experienced a significant increase in GII.4 titer after immunization with the bivalent GII.4c + GI.1 VLP vaccine.

Specificity: This antibody recognizes conserved residues distal to the HBGA binding pocket but accessible on the assembled VLP. It binds each P domain monomer at a cleft between the P1 and P2 subdomains. Norovirus (NoVs) is one of the main pathogens causing sporadic cases and large outbreaks of acute gastroenteritis, and norovirus can infect people of all ages.

Application Notes: This antibody showed broad blockade towards to all known historical GII.4 strains from 1987 onwards and neutralized the pandemic GII.P16-GII.4 Sydney strain. This antibody is also capable of blocking the VLP binding to histoblood group antigens (HBGAs). Structure revealed conserved epitopes, which were occluded on the virion or partially exposed, allowing for broad blockade with neutralizing activity. The HBGA blocking assay was used to characterize A1431 against a panel of pandemic norovirus GII.4 strains. ELISA was used to determine the binding specificity of the antibody for GII.4c VLP (PMID: 31216462).

Antibody First Published in: Lindesmith et al. Sera Antibody Repertoire Analyses Reveal Mechanisms of Broad and Pandemic Strain Neutralizing Responses after Human Norovirus Vaccination. *Immunity*. 2019 Jun 18;50(6):1530-1541. [PMID:31216462](https://pubmed.ncbi.nlm.nih.gov/31216462/)

Note on publication: Describes the generation of this antibody and study of its crystal structure.

Product Form

Size: 500 µg Purified antibody in bulk size.

Purification: Affinity Purified using a recombinant lectin column

Supplied In: PBS only.

Storage Recommendation: Store at 4°C for up to 3 months. Note, this antibody is provided without added preservatives, it is therefore recommended this antibody be handled under sterile conditions. For longer storage, aliquot and store at -20°C.

Concentration: 1 mg/ml.

Important note - This product is for research use only. It is not intended for use in therapeutic or diagnostic procedures for humans or animals.